Ligueros M, Unwin R, Wilkins M R, Humphreys J, Coles S J, Cleland J
Departamento de Farmacologia, Facultad de Medicina, Universidad de Chile, Santiago.
Clin Auton Res. 1992 Dec;2(6):373-81. doi: 10.1007/BF01831394.
The effects of six weeks of treatment with the selective peripheral alpha 1-adrenoceptor blocker terazosin, or the selective beta 1-adrenoceptor blocker atenolol on blood pressure, exercise performance and blood lipid profile were compared in a single-blind, randomized, crossover study of 17 patients with mild-to-moderate essential hypertension. Although both drugs significantly reduced blood pressure at rest, atenolol caused a larger fall in supine blood pressure (11/11 and 7.5/7.0 mmHg, atenolol and terazosin, respectively; p < 0.001). Both treatments controlled the pressor response to exercise, although a greater reduction in diastolic blood pressure was observed at the end of exercise on terazosin (74.0 +/- 5.7 and 91.6 +/- 4.0 mmHg, terazosin and atenolol, respectively; p < 0.01). Alpha 1-blocker therapy was not associated with any measurable improvement or deterioration in cardiopulmonary performance and exercise duration. Unlike atenolol, terazosin therapy had the potentially beneficial effect of reducing serum total cholesterol levels and increasing the high-density lipoprotein-cholesterol/low-density lipoprotein-cholesterol ratio.
在一项针对17例轻至中度原发性高血压患者的单盲、随机、交叉研究中，比较了选择性外周α1肾上腺素能受体阻滞剂特拉唑嗪或选择性β1肾上腺素能受体阻滞剂阿替洛尔六周治疗对血压、运动表现和血脂谱的影响。虽然两种药物均能显著降低静息血压，但阿替洛尔使仰卧位血压下降幅度更大（阿替洛尔和特拉唑嗪分别为11/11和7.5/7.0 mmHg；p<0.001）。两种治疗均能控制运动时的升压反应，不过在运动结束时，特拉唑嗪使舒张压下降幅度更大（特拉唑嗪和阿替洛尔分别为74.0±5.7和91.6±4.0 mmHg；p<0.01）。α1受体阻滞剂治疗与心肺功能和运动持续时间的任何可测量的改善或恶化均无关。与阿替洛尔不同，特拉唑嗪治疗具有降低血清总胆固醇水平和提高高密度脂蛋白胆固醇/低密度脂蛋白胆固醇比值的潜在有益作用。
